

Media Release

Zug, 3 April 2018

HBM Healthcare Investments increases net asset value per share (NAV) by 11 percent in the 2017/2018 financial year; Net profit of around CHF 115 million expected; Share price rises by 34 percent

HBM Healthcare Investments once again achieved double-digit growth in NAV of 11 percent in the 2017/2018 financial year ended 31 March. The share price rose by 34 percent. This performance significantly exceeds the increase of the MSCI World Health Care Index and the Nasdaq Biotechnology Index, which both rose by around 5%.

Based on the reported NAV of CHF 166.43 as of 31 March 2018, HBM Healthcare Investments expects an annual net profit of around CHF 115 million. Both, the private and the public companies (net of market hedging) contributed to the good result. Negative foreign exchange developments reduced the NAV by around 3% in the year under review.

The portfolio continues to be well balanced with a share of around 38 percent of net assets in private companies (including fund investments) and 52 percent in public companies (net of market hedging of around one fifth). Some of the private companies have made encouraging operational progress, which has had a positive impact in the past financial year already and should continue to add value in the coming years. The partial hedging of the market risk of the portfolio of public companies stays in place for the time being.

These results are unaudited figures, based on the current state of work on the closing of the annual financial statements. The final annual result will be published on 18 May 2018.

For further information, please contact Dr. Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM Healthcare Investments Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 710 75 77 | Fax: +41 41 710 75 78 | info@hbmhealthcare.com
www.hbmhealthcare.com